RecruitingPhase 2NCT06467539
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
Sponsor
Chang Gung Memorial Hospital
Enrollment
80 participants
Start Date
Jun 19, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.
Eligibility
Min Age: 50 YearsMax Age: 90 Years
Inclusion Criteria3
- Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
- MMSE between 10-26
- CDR 1 or 0.5
Exclusion Criteria6
- Hachinski Ischemic Score \> 4
- Substance abuse/dependence
- Parkinson disease, epilepsy, dementia with psychotic features
- Major depressive disorder
- Major physical illnesses
- Severe visual or hearing impairment
Interventions
DRUGDAOIB plus AO
oral, for 24 weeks
DRUGDAOIB plus placebo
oral, for 24 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06467539
Related Trials
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229241 locations
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
NCT071782101 location
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT041233141 location
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787278 locations